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Background/aim: Recent evidence suggests that Vitamin D deficiency may be associated with varying degrees of peripheral blood
cytopenia(s). However, the effect of Vitamin D on hematopoiesis is largely unknown. According to predefined inclusion criteria, here
we analyzed the correlation between serum Vitamin D level and hematological parameters.
Materials and methods: In the present cohort study, a total of 12.709 patients were screened. In the first data set, all patients were
included. However, in the second one, only patients (9.936) with no complete blood count (CBC) abnormality and any nutritional
deficiency (Iron, Vitamin B12 and Folic acid) were evaluated. According to the level of Vitamin D levels, patients were divided into the
four groups. Vitamin D level was 10 ng/mL in group 1, 10–20 ng/mL in group 2, 20–30 ng/mL in group 3, and above of 30 ng/mL in
group 4. Hematological parameters were analyzed and compared with Vitamin D levels. Hb level and RBC, WBC, ANC, ALC counts
were excepted as major hematological parameters.
Results: Median age of the 12709 subjects was 41 years and 61.9% was female. We have not observed statistically significant difference
between datasets regarding both demographic parameters and median Vitamin D levels. Posthoc analysis revealed a positive trend
regarding major hematological parameters through group 2 (10–20 ng/ml) when compared to other Vitamin D groups except for
platelet counts (All P values were <0.001). Regression analysis also revealed that patients who were classified under group 2 possessed a
more potent hematopoiesis when compared to others in similar age, are same sex, and having similar baseline CRP values. In contrast
to other cells, the number of thrombocytes were higher in group 1. Furthermore, all CBC and hemoglobin levels decreased with the
increased level of Vitamin D except basophil.
Conclusion: Our study reports a correlation between major hematological parameters and Vitamin D levels in a particularly large
patient population who lacks a significant confounder like chronic illnesses or conditions which may change hematological parameters.
Key words: Vitamin D, hematopoiesis, normal, healthy, hematological parameters

1. Introduction
Vitamin D3, a fat-soluble prohormone, is synthesized
in the skin after exposure to sunlight. It is further
metabolized in the liver and kidney to become active form
of Vitamin D, 1,25-Dihydroxyvitamin D (1,25-(OH)2D).
In the active form, (1alpha,25-(OH)2D), Vitamin D binds
to its receptor (VDR) to modulate gene expression and
regulate mainly ion homeostasis. It plays several roles in
the body, influencing bone health as well as serum calcium
and phosphate levels [1]. According to the degree of its
deficiency, lack of Vitamin D may lead to the development
of rickets or osteomalacia. Besides its effects on bone
metabolism or calcium homeostasis, Vitamin D modulates
growth, inflammation, neuromuscular immune function
and possibly hematopoiesis [2-6].

Hematopoiesis occurs in the bone marrow and is strictly
regulated with the help of various cytokines, hormones,
growth factors, and even vitamins to supply for a steady
state of the circulating red blood cells (RBC), white blood
cells (WBC), and platelets (PLT). Lack or deficiency of any
of these regulatory factors can potentially slow down the
hematopoietic process and lead to a certain decrease in
the production of any one or more of these three cell lines
[7]. Vitamin D deficiency is generally associated with a
slowed hematopoiesis and an outcome of varying degrees
of peripheral blood cytopenia(s) [6].
Although, there are conflicting reports about the role of
Vitamin D on hematopoiesis, there are numerous reports
indicating a correlation between Vitamin D deficiency and
anemia. Commonly proposed mechanisms, which relates
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Vitamin D deficiency to anemia, were the increased level
of inflammatory cytokines and hepcidin, which directly
suppresses hematopoiesis and interrupts iron recycling,
and reduction in the production of erythropoietin [8].
This causal relationship was most pronounced in patients
who had renal anemia and erythropoietin (EPO) hyporesponsiveness [9]. Some studies have documented a
beneficial effect of Vitamin D replacement in patients
who are diagnosed with iron deficiency anemia or anemia
of chronic disorder, even in stabilization for a need of
erythroid stimulating agent in patients with chronic
kidney disorder [10, 11]. But there are also reports,
there even exists a recently published systematic review
and metaanalysis, showing no potential beneficial effect
of Vitamin D replacement therapy on the treatment
of supplementation on hemoglobin concentration or
anemia [11,12]. Besides anemia, Vitamin D has also some
ambivalent effect on the production and life span of white
blood cells and platelets. Studies in vitro have shown
that Vitamin D suppresses colony formation of normal
human granulocyte macrophage progenitors (CFU-GM)
and, by contrast, induces differentiation of colonies into
monocyte-macrophages [13].
In this context, the role of the serum Vitamin D level
and hematopoietic parameters is a matter of debate and
needs a larger cohort of patient data. In addition, the net
effect of increased levels of Vitamin D, which exceeds the
normal threshold on hematopoiesis is not well defined.
Some reports indicate even a negative correlation between
hematological parameters and increased levels of Vitamin
D [12, 14–17]. In this term, we have analyzed the correlation
between Vitamin D and hematological parameters.
Further studies were necessary to understand exact
mechanism of this effect of Vitamin D on hematopoiesis.
For example a well-designed trial aiming to document the
effect of Vitamin D on hematopoiesis should include serial
bone marrow samples from patients who possess different
levels of Vitamin D. In addition, the level of erythropoietin
and other factors playing roles in hematopoiesis should
also be evaluated. As such an approach is neither feasible
nor acceptable, peripheral blood counts can be used as a
surrogate to analyze the integrity of hematopoiesis.
2. Materials and methods
Ethical approval was obtained from the local ethical
committee of Medipol University. Whole patient
registry of Medipol Hospital Complexes, which consist
of 8 different hospitals located in İstanbul, screened and
patients who were admitted to check-up and outpatient
internal medicine clinics and met the predefined inclusion
criteria (Figure 1) enrolled in the study. In the present
cohort study, 12.709 patients in total were screened from
2013 to 2019. In the first dataset (Dataset A) all patients
were analyzed. However, in the second one (Dataset B),
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only patients (9.936) with no complete blood count (CBC)
abnormality and any nutritional deficiency (Iron, Vitamin
B12 and Folic acid) were evaluated. We have summarized
inclusion, exclusion criteria, and the production of two
datasets (Dataset A & B) in a flow-chart (Figure 1).
First available concomitant Vitamin D level and CBC
parameters of the subjects were recorded and analyzed.
All samples were studied in the same central reference
laboratory which is located in Medipol Mega Hospital
with the same methodology and same reference ranges.
Seasonal and locational Vitamin D deficiency was defined
as harboring a Vitamin D level of 10 ng/mL or less,
according to the national guidelines.
CBC levels were analyzed by Hematology Analyzer
(XN-1000, SYSMEX, Osaka, Japan), CRP levels were
analyzed by biochemistry auto-analyzer (Cobas 6000,
Roche, Tokyo, Japan) with immunoturbidimetric method.
Serum Vitamin D levels were analyzed by ECLIA – Elecsys
Vitamin D total II - (Cobas 6000, Roche, Tokyo, Japan)
with electrochemiluminescence immunological method.
Methods were conducted according to the manufacturer
protocols.
The relationship between the distribution of CBC
parameters among different Vitamin D groups were
analyzed and reported. Hb level and RBC, WBC, ANC,
ALC counts were excepted as major hematological
parameters
2.1 Statistical analysis
All statistical analysis was performed using SAS 9.4 software
(SAS Institute Inc., Cary, NC, USA). Characterization of
the study population was conducted using descriptive
statistics including means and standard deviations of the
mean if the variable has a normal distribution or median
(range), otherwise. Discrete variables were expressed as
frequency as percentages.
Correlation
between
different
hematological
parameters and vitamin D levels were assessed using
Pearson’s and/or Spearman’s correlation tests. Beside
the correlational linear analysis between hematological
parameters and Vitamin D, we have decided to group
Vitamin D levels according to the quartiles with a
mandatory initial group including the patients who has a
certain deficiency in Vitamin D.
Differences in hematological parameters among the
four different Vitamin D groups were evaluated using
analysis of variance (ANOVA) including Tukey’s posttest
for pairwise comparison. Multivariate linear regression
analysis was used to evaluate the global effect of potential
confounders like age, sex, CRP level (reflecting the
inflammatory status) on the predictive capability of
normal vs. low or high levels of Vitamin D on individual
hematological parameters. P value less than 0.05 was
considered statistically significant.
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Figure 1: Flow chart defining the inclusion, exclusion criteria, and the production of two datasets (Datasets A & B).

3. Results
According to the distribution of Vitamin D levels, 4 different
Vitamin D groups were generated. The demographics and
the distribution of variables were given in Table 1. Group
1 consisted patients who harbor a Vitamin D level of less
than 10 ng/mL, Group 2 consisted patients who had a
Vitamin D level between 10–20 ng/mL, Group 3 consisted
patients who had a Vitamin D level between 20 –30 ng/
mL and Group 4 consisted patients with a Vitamin D level
above 30 ng/mL.
There was a significant correlation between Vitamin
D levels and hematological parameters (Table 2). When
analyzed according to the groups with a posthoc analysis,
near all hematological parameters were significantly higher
in Group 2 when compared with all other groups (Table 3).
Results were accordingly similar in all datasets and trends
of selected hematological parameters towards different
Vitamin D groups were given in
Figure 2 (Dataset A and B). Remaining parameters
were presented in Figure 3 (Datasets A and B).
Statistically significant independent predictor ability
of Group 2, when compared with the other groups, was
preserved when the analysis was adjusted for age, sex, and
concomitant CRP levels (Table 3).
4. Discussion
The absolute threshold of Vitamin D deficiency is largely
accepted as an illness. World Health Organization (WHO)

defines a deficient level as having a Vitamin D level of below
50 nmol/mL (less than 20 ng/mL) in infants1. National
Institute of Health (NIH) defines an inadequate level as
less than 20 ng/mL in all age groups2. Although there is
no consensus on optimal levels of Vitamin D measured in
serum, vitamin D level of less than 20 ng/mL (50 nmol per
liter) is defined by most experts as vitamin D deficiency
[2]. Our study indicates a deficiency rate of 58.2% in
12.709 healthy subject. An NHANES trial has documented
a 41.6% deficiency of Vitamin D in a comparable US
population regarding the same threshold of less than
20 ng/mL. But this prevalence was more pronounced in
blacks (82.1 %) and hispanics (69.2 %) [18].
A well-documented epidemiological study is lacking
regarding the Turkish population. Our study was not
designed with an intent to document the prevalence of
Vitamin D deficiency in the healthy Turkish population
but, from a statistical and epidemiological standpoint, it
can serve as a surrogate in this manner. And, our results
indicate a double-edged sword in terms of the relationship
between Vitamin D level and hematopoiesis. Subjects who
harbor a Vitamin D level between 10–20 ng/mL has the
best peripheral blood profiles. Vice versa, patients who
have a Vitamin D level of below 10 ng/mL and patients
who have a Vitamin D level of above 30 ng/mL have worse
profiles regarding the hematological parameters.
In general, the functions and metabolic roles that
Vitamin D outside the bone metabolism have always
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Table 1. The demographics and laboratory values of the patients included in 2 different
datasets*.
Dataset A (n = 12,709)

Dataset B (n = 9936)

Age (years)

41 (18–112)

41(18–96)

Sex (F/M-%)

61.9 / 38.1

57.2 / 42.8

Vitamin D Level (ng/mL)

17.29 (1.06–98.05)

17.54 (3–99.20)

Group 1

3215 (25.3)

2332 (23.5)

Group 2

4181 (32.9)

3380 (34)

Group 3

2788 (21.9)

2248 (22.6)

Group 4

Number of Subjects - n, (%)

2525 (19.9)

1976 (19.9)

CRP (mg/L)

1.45 (0–5)

1.47 (0–5)

Hb (g/dL)

13.46±1.73

13.93±1.20

RBC (106/µL)

4.79±0.54

4.87±0.46

MCV (fl)

83.96±5.79

84.77±4.68

RDW (%)

13.78±1.55

13.43±1.08

WBC (10 /µL)

6.78±1.45

6.91±1.37

ANC (10 /µL)

3.75±1.09

3.80±1.04

ALC (103/µL)

2.24±0.64

2.30±0.61

AMoC (10 /µL)

0.58±0.17

0.59±0.17

AEoC (103/µL)

0.18±0.15

0.19±0.16

ABaC (10 /µL)

0.03±0.02

0.03±0.02

Plt (103/µL)

241.10±60.99

242.05±52.74

MPV (fl)

10.23±0.97

10.23±0.89

PDW (fl)

12.22±2.01

12.22±1.92

3

3

3

3

*CRP: C Reactive Protein, Hb: Hemoglobin, RBC: Red Blood Cells, MCV: Mean Corpuscular
Volume, RDW: Red Cell Distribution Width, WBC: White Blood Cells, ANC: Absolute
Neutrophil Count, ALC: Absolute Lymphocyte Count, AMoC: Absolute Monocyte Count,
AEoC: Absolute Eosinophil Count, ABaC: Absolute Basophil Count, Plt: Platelets, MPV:
Mean Platelet Volume, PDW: Platelet Distribution Width

been an interesting field for researchers. There has been
a cumulative literature correlating Vitamin D deficiency
with inflammation, cardiovascular disorders, and even
cancer. Although Vitamin D gained a wide reputation with
the new studies in the literature and replacement became
a standard of care for many clinicians with an aim to
increase Vitamin D up to 50 ng/mL or more, many recent
reports still question this approach.
Manson et al., conducted a randomized, double-blind,
placebo-controlled trial, with a two-by-two factorial
design, to examine the benefits and risks of vitamin D3
(cholecalciferol) at a dose of 2000 IU per day and marine
n−3 fatty acids at a dose of 1 g per day as the primary
prevention of cancer and cardiovascular disease among
25,871 men who were 50 years of age or older and women
who were 55 years of age or older. This trial has shown
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no benefit of replacing Vitamin D on primary prevention
of cancer or cardiovascular disease despite an increase of
the mean Vitamin D level from 29.8 ng/mL to 41.8 ng/
mL after replacement [19]. In addition, Ginde et al. have
also conducted a randomized, double-blind, placebocontrolled, phase 3 trial of early vitamin D3 supplementation
in critically ill, vitamin D-deficient patients who were
at high risk of death. They have concluded that early
administration of high-dose enteral vitamin D3 did not
provide more advantage over placebo with respect to 90day mortality or other nonfatal outcomes among critically
ill, vitamin D-deficient patients [20].
Pittas et.al randomized 2423 prediabetic participants
into placebo and Vitamin D supplementation groups. They
have concluded that among persons at high risk of type
2 diabetes and not selected for vitamin D insufficiency,
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Table 2. Correlation matrix of different hematological parameters and
Vitamin D.
Dataset A
(n = 12,709)

Dataset B
(n = 9936)

* Vit D (r and P values)
Age

0.117

<0.001†

0.112

<0.001†

–0.010

0.256

–0.017

0.092

0.027

†

0.002

- 0.020

0.044†

–0.043

<0.001†

–0.057

<0.001†

MCV (fl)

0.062

†

<0.001

0.012

0.227

RDW (%)

–0.023

0.009†

0.034

<0.001†

WBC (103/µL)

–0.043

<0.001†

–0.046

<0.001†

ANC (103/µL)

–0.036

<0.001†

–0.031

0.002†

ALC (10 /µL)

–0.016

<0.001

–0.042

<0.001†

AMoC (103/µL)

–0.002

0.811

–0.004

0.674

AEoC (103/µL)

- 0.020

0.027†

–0.031

0.002†

CRP (mg/l)
Hb (g/dL)
RBC (106/µL)

3

ABaC (103/µL)

†

0.014

0.106

0.018

0.067

- 0.059

<0.001†

–0.029

0.004†

MPV (fl)

0.014

0.123

0.011

0.283

PDW (fl)

0.005

0.541

0.006

0.558

Plt (103/µL)

*Bivariate correlation analysis between Vitamin D levels and hematological
parameters
†
P < 0.05.
Table 3. Regression model adjusted for age, gender and CRP*
Dataset A

Dataset B

* Vitamin D
(Group 2 vs other groups)

β (Coef.)

%95(CI)

t

P value

β (Coef.) %95(CI)

t

Hb (g/dL)

–0.12

–0.17 – –0.07

–4.77

<0.001†

–0.05

–0.09 – –0.02

–2.93

0.003†

RBC (106/µL)

–0.03

–0.05 – –0.14

–3.59

<0.001†

–0.01

–0.03 – 0.01

–1.43

<0.001†

MCV (fl)

–0.05

–0.26 – 0.17

–0.42

0.676

–0.05

–0.24 – 0.15

–0.51

0.609

RDW (%)

0.14

0.08 – 0.19

4.65

<0.001

0.08

0.04 – 0.13

3.60

<0.001†

WBC (103/µL)

–0.12

–0.17 – –0.66

–4.35

<0.001†

–0.09

–0.14 – –0.03

–2.91

0.004†

ANC (10 /µL)

–0.05

–0.09 – –0.01

–2.26

†

0.024

–0.03

–0.07 – 0.02

–1.19

0.010†

ALC (103/µL)

–0.06

–0.08 – –0.04

–5.13

<0.001†

–0.05

–0.08 – –0.02

–3.88

<0.001†

AMoC (10 /µL)

–0.01

–0.01 – 0.01

–2.34

†

0.019

–0.01

–0.01 – 0.01

–1.80

0.071

AEoC (103/µL)

–0.01

–0.01 – 0.01

–0.82

0.010†

–0.01

–0.01 – 0.01

–0.04

0.004†

ABaC (10 /µL)

–0.01

–0.01 – 0.01

–1.34

0.182

–0.01

–0.01 – 0.01

–1.09

0.277

Plt (10 /µL)

–3.31

–5.51 – –1.10

–2.93

0.003

–2.33

–4.48 – –0.19

–2.13

0.033†

MPV (fl)

0.03

–0.01 – 0.07

1.74

0.081

0.03

–0.01 – 0.08

1.73

0.084

PDW (fl)

0.07

–0.01 – 0.15

1.88

0.060

0.06

–0.02 – 0.14

1.49

0.137

3

3

3

3

†

†

P value

*Independent variables included in the model are: Vitamin D groups (Group 2 vs others), sex, age and CRP levels, dependent variables
were hematological parameters accordingly.
†
P < 0.05
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Figure 2. Trends of hematological parameters towards different Vitamin D groups (Datasets A and B). We have not observed any
significant difference between Datasets A and B. Compared to Group 2 (Vitamin D was less than 10 ng/dL), low level of hemoglobin
was observed in Group 1 (Vitamin D was between 10–20 ng/dL), which was associated with the decreased number of erythrocytes,
leukocytes, and lymphocytes, while the number of thrombocytes was higher, and the number of neutrophils was not significantly
different. Notably that all these parameters were decreased in group 4 (Vitamin D was above of 30 ng/dL). The number of patients/per
groups were given in Table 1. *One Way ANOVA test was used to compare the means of hematological parameters in different Vitamin
D groups.
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Figure 2. (Continued).

vitamin D3 supplementation at a dose of 4000 IU per day
did not result in lowering the risk of diabetes significantly
compared to placebo despite a well pronounced mean
Vitamin D levels between two groups (54.3 vs 28.2 ng/
mL) [21]. In a metaanalysis of 33 randomized trials, effects

of supplementation with calcium, vitamin D, or both
on fracture rates were investigated in older communitydwelling adults (age ≥ 50). There was no reduction in
risk for hip fracture or vertebral, nonvertebral, and total
fractures for any supplementation intervention. The

1947

OLMUŞÇELİK and SEVİNDİK / Turk J Med Sci

Figure 3. Trends of hematological parameters in different Vitamin D groups (Datasets A and B). We have not observed any significant
difference between Datasets A and B. Compared to Group 2 (Vitamin D was less than 10 ng/dL), low number of monocytes, and
basophiles were observed in Group 1 (Vitamin D was between 10–20 ng/dL), while eosinophiles were not affected significantly. Notably
that both the number of monocytes and eosinophiles were decreased in Group 4 (Vitamin D was above of 30 ng/dL), while the number
of basophiles were not changed significantly. The number of patients per groups were given in Table 1. *One Way ANOVA test was used
to compare the means of hematological parameters in different Vitamin D groups.
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results applied to subgroups with 25-hydroxyvitamin D
levels lower than 20 ng/mL or with previous fractures [22].
Despite all these clear evidences showing no benefit of
routine Vitamin D replacement on any medical outcome,
prescribing Vitamin D supplements in general practice
aiming very high levels of 25(OH) Vitamin D still remains
as a well-accepted clinical approach.
There are also conflicting data in terms of the benefit
of Vitamin D replacement on hematological parameters.
Arabi et al. have published a systematic review and
metaanalysis with a purpose to investigate the effect of
vitamin D supplements on hemoglobin concentration
in subjects aged 17.5–68 years old using randomized
controlled trials (RCTs), and they concluded that
supplementation with vitamin D had no significant effect
on hemoglobin and ferritin levels, while positive effects on
transferrin saturation and iron status were observed [12].
Since the impact of Vitamin D on red blood cell
formation has not been well studied so far, Doudin et al.
aimed to assess the putative link between serum 25(OH)
Vitamin D concentrations and hematological markers of
erythropoiesis in a large cohort of German adolescents
aged 11 to 17. They were able to demonstrate significant
and inverse correlations between 25(OH)D levels and
several hematological parameters including hemoglobin
concentration, mean corpuscular hemoglobin, red
blood cell count, and soluble transferrin receptor, whereas,
in contrast, serum 25(OH)D was positively correlated
to the mean corpuscular volume of erythrocytes. Also,
multivariate models have confirmed an inverse correlation
between Vitamin D sufficiency and hematological
parameters. Unfortunately, they were not able to conclude
a specific group in which patients showed the highest
tendency to a healthy erythropoiesis. Their data lacked
among other cell lines of hematopoiesis like white blood
cells or thrombocytes [17].
Our large enough observational study clearly indicates
a worsened hematopoiesis in patients with relatively higher
Vitamin D levels in both general population (Dataset
A) and patients who harbors no baseline hematological
abnormality and any deficiency in iron or Vitamin B12

(Dataset B). Hospital-based screening should be noted
as a main limitation to our current study. A populationbased screening study should be conducted in order to
reflect an epidemiologically relevant data. Nonetheless, as
indicated in the methodology of our current manuscript,
the majority of patients have visited check-up clinics, and
a refined dataset (Dataset B) also reflected parallel results
when compared with the whole population (Dataset
A). Strength of our study is that it draws a clear picture
regarding the parameters in specified Vitamin D Groups
except for thrombocyte count. Thrombocyte count
showed a constant decline with increasing Vitamin D
levels. Current literature reports correlational analysis
between hematological parameters and Vitamin D but
lacks a grouped approach in documenting a maximal
level in any of the groups. We believe that this will induce
some mechanistic researches to document this kind
of schizophrenic effect of Vitamin D on hematological
parameters and hematopoiesis.
5. Conclusion
Our study reports a statistically significant correlation
between major hematological parameters and Vitamin D
levels in a particularly large patient population who lacks a
significant confounder like chronic illnesses or conditions
which can contribute to and potentially serves as a bias.
Furthermore, the group who has a maximal capacity of
hematopoiesis are the ones harboring Vitamin D levels
between 10–20 ng/mL.
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